Fibrostenosis Focused Therapeutics - RFP
Funds research and development of innovative, non-surgical therapies targeting fibrosis in Crohn's disease and ulcerative colitis, emphasizing translational science and product-focused solutions.
Funder: Crohn's and Colitis Foundation
Due Dates: March 30, 2023 (LOI) | July 24, 2023 (Full Proposal) | May 31, 2026 (LOI) | August 14, 2026 (Full Proposal)
Funding Amounts: Up to $450,000 per project for one year; potential annual renewal; indirect costs capped at 10%.
Summary: Funds development of non-surgical, product-focused therapies for fibrotic complications in IBD, targeting innovative translational approaches.
Key Information: Letter of Intent (LOI) required; full proposals by invitation only; open to companies and academic groups with commercialization focus.
Description
This opportunity supports the development of innovative, non-surgical therapeutic products aimed at treating fibrosis (fibrostenosis) in patients with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. The funder seeks proposals that translate clinical observations or published human IBD evidence into therapies that modulate fibrotic pathways or leverage multidisciplinary approaches. The primary goal is to address the unmet need for effective, product-based solutions for IBD-related fibrosis beyond surgical interventions.
